Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial

Bradley J. Monk; Stanley B. Kaye; Andrés Poveda; Thomas J. Herzog; Miguel Aracil; Antonio Nieto; Nadia Badri; Trilok V. Parekh; Adnan Tanović; Carlos M. Galmarini

doi:10.1016/j.ygyno.2013.10.032

Journal article

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial

Bradley J. Monk, Stanley B. Kaye, Andrés Poveda, Thomas J. Herzog, Miguel Aracil, Antonio Nieto, Nadia Badri, Trilok V. Parekh, Adnan Tanović and Carlos M. Galmarini

Gynecologic Oncology, Vol.132(1), pp.176-180

2014

DOI: https://doi.org/10.1016/j.ygyno.2013.10.032

PMID: 24211400

Metrics

4 Record Views

Details

Title: Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial
Creators: Bradley J. Monk (Author) - Creighton University
Stanley B. Kaye (Author)
Andrés Poveda (Author)
Thomas J. Herzog (Author)
Miguel Aracil (Author)
Antonio Nieto (Author)
Nadia Badri (Author)
Trilok V. Parekh (Author)
Adnan Tanović (Author)
Carlos M. Galmarini (Author)
Additional links: http://dx.doi.org/10.1016/j.ygyno.2013.10.032
Publication Details: Gynecologic Oncology, Vol.132(1), pp.176-180
Number of pages: 176-180
Identifiers: 991005931230202656
Academic Unit: School of Medicine; Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial

Related links

Metrics

Details